Best deal of the week



Instruction for use: Mometasone (Mometasonum)

I want this, give me price

Pharmacological group


Nosological classification (ICD-10)

J01 Acute sinusitis

Inflammation of the sinuses, Inflammatory diseases of the paranasal sinuses, Purulent inflammation of the paranasal sinuses, Infectious-inflammatory diseases of ENT organs, Infection of the sinuses, Combined sinusitis, Exacerbation of sinusitis, Acute inflammation of the paranasal sinuses, Acute bacterial sinusitis, Acute sinusitis in adults, Subacute sinusitis, acute Sinusitis, sinusitis

J30.1 Allergic rhinitis caused by the pollen

hay fever, Hypersensitivity to pollen, Polypoid allergic rhinosinusitis, Seasonal hay fever, rhinitis

J30.2 Other seasonal allergic rhinitis

Allergic rhinitis seasonal, Seasonal rhinitis of an allergic nature

J30.3 Other allergic rhinitis

Allergic rhinitis all year round, Allergic rhinoconjunctivitis

J32 Chronic sinusitis

Allergic rhinosinusopathy, purulent sinusitis, Catarrh nasopharyngeal area, Catarrh of the sinuses, Exacerbation of sinusitis, chronic Sinusitis

J44.9 Chronic obstructive pulmonary disease, unspecified

Obstructive pulmonary diseases, Bronchial obstruction, bronchial obstruction, Exacerbation of chronic obstructive pulmonary disease, reversible airflow obstruction, Reversible airway obstruction, panbronchiolitis, Panbronhit, COPD, Chronic pulmonary infection, Chronic infection of the lower respiratory tract, Chronic obstructive pulmonary disease, Chronic obstructive pneumonia, Chronic lung disease, Chronic obstructive pulmonary disease, Chronic bronchopulmonary disease, Chronic broncho-pulmonary diseases, Airway obstruction

J45 Asthma

Asthma physical effort, status asthmaticus, Bronchial asthma, Asthma lung flow, Bronchial asthma with obstruction of sputum discharge, Bronchial asthma heavy currents, Bronchial asthma physical effort, hypersecretory asthma, Hormone-dependent form of bronchial asthma, Relief of asthma attacks in bronchial asthma, Non-allergic asthma, nocturnal asthma, Exacerbation of asthma, Asthma attacks, Endogenous forms of asthma, Night asthma, Cough with bronchial asthma

L20 Atopic dermatitis

Itchy atopic eczema, Common neurodermatitis, Allergic skin diseases, Allergic skin diseases of non-infectious etiology, Allergic skin diseases of non-microbial etiology, Allergic skin diseases, Allergic skin lesions, Allergic manifestations on the skin, Allergic dermatitis, Allergic diathesis, Allergic itching dermatosis, Allergic Skin Disease, Allergic skin irritation, Dermatitis allergic, Atopic dermatitis, Dermatosis allergic, Diathesis exudative, Skin Allergic Disease, Skin allergic reaction to medicinal and chemical preparations, Skin reaction to medication, Skin and allergic disease, Acute eczema, Chronic atopic dermatitis, Exudative diathesis, Itching allergic dermatosis

L21 Seborrheic dermatitis

Dermatitis seborrheic, Increased sebum separation, Seborrheic Eczema, Seborrheic dermatitis of the scalp, Seborrheic pyodermatitis, Seborrhea, Eczema seborrheic

L30.9 Dermatitis, unspecified

Allergic dermatoses complicated by a secondary bacterial infection, Anal eczema, Bacterial maturation, Varicose Eczema, Venous dermatitis, Inflammation of the skin, Inflammation of the skin upon contact with plants, Inflammatory Skin Diseases, Inflammatory skin reactions, Inflammatory processes of the skin, Hypostatic dermatitis, Fungal Eczema, Fungal dermatosis, Dermatitis, Dermatitis is stagnant, Dermatitis and eczema in the anal area, Dermatitis acute contact, Perianal dermatitis, Dermatosis, Dermatosis of the scalp, Dermatosis of psoriasis, Dermatosis with persistent itching, Dermatoses, Dermatoses itchy, Other itching dermatoses, Significant eczematous manifestations, Itching with, dermatoses, Itching eczema, True eczema, Skin reaction to insect bites,Skin itching with dermatosis, Constitutional eczema, Weeping eczema, Drowsing inflammatory skin disease, Dying Infectious-Inflammatory Skin Disease, Non-allergic dermatitis, Nummular eczema, Acute contact eczema, Acute inflammatory skin disease, Acute dermatosis, Acute severe dermatosis, Perianal dermatitis, Superficial dermatosis, Subacute Contact Eczema, Simple dermatitis, Occupational dermatitis, Psychogenic dermatosis, Bubble dermatitis of newborns, Pustular eruptions, Irritation and redness of the skin, Low-flammable eczema, Dry atrophic eczema, Dry eczema, Toxic dermatitis, Ear eczema like dermatitis, Chronic eczema, Chronic dermatosis, Chronic common dermatosis, Scaly papular dermatosis, Eczema, Eczema anal region, Eczema of the hands, Eczema Contact, Eczema lichenized, Eczema Nummular, Eczema acute, Eczema acute contact, Eczema subacute, Eczematous dermatitis, Eczema-like rashes, Ecome exogenous, Endogenous eczema, Gluteal dermatitis, Restricted itchy dermatitis

L40 Psoriasis

Chronic psoriasis with diffuse plaques, Generalized psoriasis, Psoriasis of the scalp, Psoriasis of the scalp, Generalized form of psoriasis, Psoriasis dermatitis, Psoriasis complicated by erythroderma, Invalidative psoriasis, Isolated psoriatic plaque, Exfoliative psoriasis, Psoriatic Erythroderma, Psoriasis with eczematosis, Hyperkeratosis in psoriasis,Inverse psoriasis,Psoriasis eczematous, Dermatosis of psoriasis, Psoriasis of the genitals, Psoriasis with lesions of hairy areas of skin, Erythrodermal psoriasis, Chronic psoriasis of the scalp, Chronic psoriasis, Ordinary psoriasis, Refractory psoriasis, Kebner phenomenon, Scaly lichen

Code CAS105102-22-5


Mometasone furoate is a white powder with a yellowish or grayish tinge. Virtually nerastvorim in water, slightly soluble in octanol, moderately - in ethyl alcohol. Molecular weight 521.4.


Pharmacological action - anti-inflammatory, antiallergic, antipruritic, antiexudative, glucocorticoid.

Induces lipocortins - proteins that inhibit phospholipase A2. As a result, the arachidonic acid is liberated from membrane phospholipids and the biosynthesis of PG (prostaglandins), leukotrienes is disrupted.

With intranasal use, systemic bioavailability is less than 0.1% of the dose. The absorption of mometasone from 0.1% of the cream through the normal skin is 0.4% of the dose for 8 hours after the application without bandage. With inflammation or damage to the skin, absorption accelerates.

With daily application of the cream to children over 2 years with allergic dermatitis therapeutic effect is manifested in 3 weeks.

Application of Mometasone

Locally: weakening and elimination of inflammatory phenomena and itching in dermatoses (including lesions of hairy areas of skin), amenable to glucocorticoid therapy in adults and children aged 2 years (including psoriasis, atopic dermatitis, seborrheic dermatitis).

Intranasally: allergic rhinitis (seasonal and year-round) in adults and children aged 2 years, exacerbation of sinusitis (complex therapy with antibiotics) in adults and children over 12 years, prevention of seasonal allergic rhinitis of moderate and severe course in adults and children over 12 years of age (Recommended for 2-4 weeks before the expected start of the dusting season).

Inhalation: bronchial asthma of any severity (including in patients who previously used both inhalation and systemic HA, as well as inadequate effectiveness of previous therapy without the use of HA); COPD (chronic obstructive pulmonary disease) - from moderate severity to very severe.


Hypersensitivity; For intranasal use: the presence of an untreated local infection involving the mucous membrane of the nasal cavity, recent surgery or injury to the nose (until the wound is healed); Tuberculosis infection (active or latent) of the respiratory tract, untreated fungal, bacterial, viral systemic infection or infection caused by Herpes simplex with eye damage (as an exception, the appointment of mometasone in these cases is possible on the instructions of the doctor with great care).

pregnancy and lactation

Perhaps, if the expected effect of therapy exceeds the potential risk to the fetus and the child.

The action category for fetus by FDA is C.

Side effects

Locally (ointment, cream, lotion): burning, itching, tingling and tingling sensations, paresthesia, folliculitis, acne, skin atrophy, hypertrichosis, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, striae, sweating.

Intranasal: burning, itching, irritation, dryness and atrophy of the nasal mucosa, nosebleeds, pharyngitis, candidiasis, bronchospasm, secondary infection.

Update of information

Adverse effects with inhalation

With inhalation application

Most often: candidiasis of the mouth, pharyngitis, dysphonia, headache.

Rarely: dry mouth and throat, dyspepsia, weight gain, palpitations.

In some cases, in predisposed patients: the occurrence of hypersensitivity reactions, including rash, hives, itching, erythema, as well as swelling of the eyes, face, lips and throat.

When using inhalation GC for the treatment of bronchial asthma, it is possible to develop bronchospasm and increase the number of wheezing in the lungs immediately after inhalation.

Systemic effects (especially when used in high doses and for a long time): suppression of adrenal cortex function, growth retardation in children and adolescents, demineralization of bone tissue, glaucoma, increased intraocular pressure, cataract development.


Update of information

The interaction of mometasone with other drugs

Ointment, cream, lotion. There is no data on interactions with other drugs.

Spray nasal. Combined therapy with loratadine was well tolerated by patients. Studies of interaction with other drugs have not been conducted.

Powder for inhalation. With the simultaneous use of mometasone in the form of inhalations and ketoconazole (an inhibitor of the isoenzyme CYP3A4), an increase in the concentration of mometasone in the blood plasma and a small (at the border of statistical significance) decrease in AUC0-24 cortisol in the blood plasma. It is unlikely that these changes are of clinical significance.


Symptoms of hypercortisy can develop.

Treatment: withdrawal of the drug, if necessary - correction of electrolyte imbalance.

With intranasal use: spotting

With intranasal use: spotting (mucus or blood clots) from the nasal passages; The applications are stopped, no special treatment is required.

Routes of administration

Applicative, intranasal inhalation, inhalation.


Not intended for use in ophthalmology. It is necessary to regularly monitor the function of the adrenal glands (so as not to miss the symptoms of hypercorticism). Newborns, whose mothers used HA during pregnancy, should be carefully examined to identify possible hypofunction of the adrenal glands.

In case of development of local infections of the nose or pharynx, mometasone is gradually canceled. Treatment of children is carried out according to strict indications and under medical supervision, tk. Possible the development of systemic side effects.

Someone from the Ireland - just purchased the goods:
Pimafucort ointment 15gr